Gilead Sciences

Biotechnology

GILD

$ 75 (0.64)%

Share price

$ 93 bn

Market Cap

$ 111 bn

Enterprise Value

Carbon footprint

GHG emissions per $ 1 mln investment

0.02x the weighted average for S&P 500

FY2022

Primary Climate Goal

Proj. YOY change in GHG emissions (Scope 1 + 2)

Weaker than the -8% weighted average for S&P 500

FY2023

Gilead Sciences aims to reduce Scope 1 + 2 by 46% by 2030 from a base year 2019

1.5°C

Secondary Climate Goal

Gilead Sciences aims to reduce Scope 3 by 15% by 2030 from a base year 2019

1.5°C

GHG emissions and Carbon intensity

Gilead Sciences reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2022 at 82 Kt (-6.8 /-7.6% y-o-y). Also positively, carbon intensity was down at 3 t (-0.3 /-9.1% y-o-y).

Gilead Sciences's Scope 3 emissions soared to 38 Kt (+5.1/+16% y-o-y). The growth accelerated compared to the long-term upward trend (CAGR of +6.1% since 4Q'16).

The company is committed to reducing Scope 1 + 2 by 46% by 2030 from a base year 2019, which translates into the estimated reduction of -4.4 Kt per annum over the period of FY2023 - FY2030. This science-based target is aligned with Paris Agreement to limit global warming to 1.5°C above pre-industrial levels.

Date	Total CO2e emissions (market-based Scope 1 & 2) (Kt)	Scope 1	Scope 2	Scope 3	Revenue (USDm)	Carbon intensity (tons of CO2e) / (USDm)
2022Q4	82	55	27		27,281	3
2021Q4	89	55	34		27,305	3.3
2020Q4	80	48	32		24,689	3.2
2019Q4	87	52	33		22,449	3.9
2018Q4	72	47	26	38	22,127	3.3
2017Q4	76	47	29	33	26,107	2.9
2016Q4	82	45	37	32	30,390	2.7